Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)
Condition(s):Metastatic Castration-Resistant Prostate Cancer PatientsLast Updated:July 20, 2023Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Metastatic Castration-Resistant Prostate Cancer PatientsLast Updated:July 20, 2023Active, not recruiting
Condition(s):Colorectal CancerLast Updated:October 25, 2018Completed
Condition(s):Primary Peritoneal Cavity Cancer; Recurrent Ovarian Epithelial CancerLast Updated:July 24, 2019Completed
Condition(s):Lung CancerLast Updated:July 20, 2016Completed
Condition(s):Thyroid CancerLast Updated:June 16, 2021Completed
Condition(s):Breast CancerLast Updated:February 11, 2013Completed
Condition(s):Liver CancerLast Updated:December 8, 2021Completed
Condition(s):Colorectal CancerLast Updated:March 7, 2014Withdrawn
Condition(s):Pancreatic CancerLast Updated:December 24, 2012Completed
Condition(s):Unspecified Childhood Solid Tumor, Protocol SpecificLast Updated:February 5, 2013Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.